3 Psychedelic Sector Leaders That Investors Need To Be Aware OfPsyched Wellness Announces New OTCQB Ticker: PSYCF2 Psychedelic Bellwethers That Are Gearing Up To Go Public In 2021Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use DisorderMindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial ExperiencePure Extracts (CSE:PULL) – A Leading Canadian Mushroom Extraction PlatformPsyched Wellness’ Mycological Research Continues To Take Serious Strides ForwardMindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic TherapeuticsPure Extracts Continues To Build Out Its Comprehensive Mushroom Extraction PlatformMYND Life Sciences Inc. Closes $2.4 Million Private Placement and Provides Update on Planned ListingTryp Therapeutics Appoints Dr. William K. Schmidt to Its Scientific Advisory BoardCYBIN Provides Update on Patent Filings & Development of Therapeutics ProgramNuminus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic ProductsPsyched Wellness Commences Antioxidant and Anti-Inflammatory Study on MuscimolMindset Generates Promising In Vitro Results from Third Patent Family of Novel Psychedelic Compounds Suggesting Range of3 Drug Development Companies Leveraging Psychedelic Compounds In Clinical TrialsEntheon Biomedical Announces Investment and Business Arrangement with Heading Health LLCPsyched Wellness Has Commenced Research on Muscimol for Various AilmentsAion Therapeutic Announces Closing of Non-Brokered Private Placement

Nova Mentis Life Science Announces Receipt of Pilz Shareholder Approval

Nov 18, 2020 • 3:24 PM EST
4 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that, further to its news release dated November 2, 2020, the shareholders of Pilz Bioscience Corp. (“Pilz“) have approved the amalgamation agreement between Pilz and 1271642 B.C. Ltd. (“Nova Subco“), a wholly-owned subsidiary of the Company, pursuant to which the Company will acquire all of the issued and outstanding common shares in the capital of Pilz (the “Transaction”).

Pilz is a research driven biotechnology company that aims to develop medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet therapeutic needs.  Pilz’s focus is on Autism Spectrum Disorder (ASD), and its initial research has centred on developing a unique and proprietary system for diagnosing and treating ASD, with first-in-class psilocybin-based therapeutics.

The Pilz research and development program is led by the distinguished Dr. Marvin S. Hausman MD. Dr. Hausman is an Immunologist and Board-Certified Urological Surgeon with more than 30 years of drug research and development experience with various pharmaceutical companies, including Bristol-Myers International, Mead-Johnson Pharmaceutical Co., E.R. Squibb, Medco Research, and Axonyx.

Dr. Hausman is well-supported in his research efforts at Pilz, by Dr. Julia Perederiy, an established research neuroscientist, and Dr. Viviana Trezza, Head of Pharmacology, Roma Tre University, Rome, Italy. The goal of both scientists is to investigate the brain mechanisms underlying functional and dysfunctional socio-emotional behavior, especially in Autism Spectrum Disorder (ASD).

The Transaction
The Transaction will be effected by way of a “three-cornered” amalgamation (the “Amalgamation“), in which: (a) Nova Subco will amalgamate with Pilz to form an amalgamated company (“Amalco“); (b) all issued and outstanding shares of Pilz will be exchanged for common shares of the Company on a 1:1 basis; and (c) Amalco will become a wholly-owned subsidiary of the Company and shall be renamed Pilz Bioscience Corp. upon closing.

Pursuant to the Transaction, Nova will acquire 100% of the issued and outstanding shares of Pilz at a ratio of one Nova common share (each, a “Nova Share”) for every one Pilz common share (each, a “Pilz Share”). Upon closing of the Transaction, it is expected that Nova will issue 50,006,332 Nova Shares to the shareholders of Pilz. Of these shares, 12,250,000 are subject to a voluntary pooling agreement whereas certain Pilz shareholders have agreed to resale restrictions on their Nova Shares: 20% to be released upon closing of the Transaction, a further 40% to be released three (3) months following closing, and the remaining 40% to be released six (6) months following closing.

In connection with the Transaction, Dr. Marvin S. Hausman MD shall be appointed Chairman of Nova’s Scientific Advisory Board and Amalco’s Chief Medical Officer.

About Pilz Bioscience Corp.
Pilz Bioscience Corp. (“Pilz”) is a biotechnology company developing medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet therapeutic needs. The initial focus is on Autism Spectrum Disorder (ASD). The company intends to leverage a unique systems-level scientific approach that integrates inflammation, oral/gut/brain axis, and behavior. Pilz aims to lead the global effort in design of effective and comprehensive diagnostic/monitoring programs and first-in-class therapeutics.

About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. (formerly Liberty Leaf Holdings Ltd.) is a Canadian-based, public company whose focus is to build and support a diversified portfolio of health and wellness businesses. Key holdings include its wholly-owned subsidiary, Nova Mentis Biotech Corp., a R&D driven company focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes – Just Kush Enterprises, an Okanagan BC based, Health Canada Standard Licensed facility focused on the cultivation of premium, small batch Kush dominant cultivars.

For further information on the Company, please visit https://www.novamentis.ca or email info@novamentis.ca

On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.